快速清除放射性配体[177Lu]Lu-P17-087治疗mCRPC的1期剂量递增研究
该1期研究纳入9例PSMA高表达的进展性mCRPC患者,采用患者内自适应剂量递增方案,评估快速清除配体[177Lu]Lu-P17-087的安全性、药代动力学、剂量学及初步抗肿瘤活性。结果显示血液有效半衰期0.52小时,肾脏吸收剂量0.39±0.26 Gy/GBq、红骨髓0.07±0.01 Gy/GBq,最高7.4 GBq未见剂量限制性毒性或3/4级血液学不良事件,8/9例PSA下降、2/9例PSA下降≥50%。
要点
- 血液有效半衰期0.52小时,肾脏吸收剂量0.39±0.26 Gy/GBq,红骨髓0.07±0.01 Gy/GBq
- 最高7.4 GBq未见剂量限制性毒性或3/4级血液学不良事件
- 8/9例(88.9%)PSA较基线下降,2/9例(22.2%)PSA下降≥50%
核心结论
- 该1期剂量递增研究显示[177Lu]Lu-P17-087在体内快速清除,小样本中早期正常器官毒性低,每周期高达7.4 GBq可行并伴初步抗肿瘤活性。
研究设计与样本
- 1期剂量递增研究,纳入9例进展性mCRPC且PET/CT示PSMA高表达患者。
- 采用患者内自适应剂量递增方案,给药活度分为低(1.1-2.3 GBq)、中(3.7-5.6 GBq)、高(约7.4 GBq)三档。
- 于注射后1-96小时行全身平面显像、24小时行定量SPECT/CT,采用OLINDA/EXM进行剂量学分析。
- 安全性按CTCAE v5.0评估,抗肿瘤疗效以PSA应答和PSMA PET/CT的RECIP 1.0影像学应答评价。
主要发现
- 血液有效半衰期为0.52小时,呈快速药代动力学。
- 肾脏吸收剂量为0.39±0.26 Gy/GBq,红骨髓为0.07±0.01 Gy/GBq。
- 病灶呈持续滞留,淋巴结转移灶半衰期为22.9小时。
- 剂量递增方案耐受良好,即使最高给药活度7.4 GBq也未观察到剂量限制性毒性或3/4级血液学不良事件。
- 8/9例(88.9%)PSA较基线下降,2/9例(22.2%)PSA较基线下降50%;PSA下降幅度随给药活度水平不同而变化。
关键数值与推荐
- 给药活度分档:低1.1-2.3 GBq、中3.7-5.6 GBq、高约7.4 GBq。
- 剂量学分析时间点:全身平面显像为注射后1-96小时,定量SPECT/CT为注射后24小时。
- 安全性评估采用CTCAE v5.0,影像学应答评价采用PSMA PET/CT的RECIP 1.0标准。
- 生化应答指标:PSA较基线下降及PSA较基线下降50%。
临床怎么用
- 该快速清除配体在高达7.4 GBq/周期时未见剂量限制性毒性,支持后续在更大样本中探索剂量策略。
- 肾脏与红骨髓吸收剂量较低,提示正常器官早期毒性风险有限,但需更长随访确认。
- 多数患者可见PSA下降,但PSA下降≥50%比例有限,疗效需更大规模研究验证。
局限性
- 样本量小(9例),结论需更大规模研究验证。
- 随访时间有限,疗效与安全性的长期数据尚不充分。
- 最佳给药策略尚未确定,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the rapid systemic clearance and favorable kinetic profile of the novel DOTA(GA)2-conjugated ligand [177Lu]Lu-P17-087, this phase 1 study aimed to systematically evaluate the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of escalating therapeutic activities in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nine patients with progressive mCRPC and high prostate-specific membrane antigen (PSMA) expression on PET/CT were enrolled. An adaptive intrapatient dose-escalation protocol was used, with administered activities categorized as low (1.1-2.3 GBq), mid (3.7-5.6 GBq), and high (∼7.4 GBq). Serial whole-body planar scintigraphy (1-96 h postinjection) and quantitative SPECT/CT (24 h postinjection) were acquired for dosimetry analysis using OLINDA/EXM. Safety was assessed per Common Terminology Criteria for Adverse Events version 5.0. Antitumor efficacy was evaluated by prostate-specific antigen (PSA) response and radiographic response using PSMA PET/CT (RECIP 1.0). Activity-associated PSA changes were summarized descriptively across administered activity levels. Results: [177Lu]Lu-P17-087 exhibited rapid pharmacokinetics (effective half-life of 0.52 h in blood). This fast-clearance profile yielded low absorbed doses to dose-limiting organs, including the kidneys (0.39 ± 0.26 Gy/GBq) and red marrow (0.07 ± 0.01 Gy/GBq). Conversely, lesions showed sustained retention, particularly in lymph node metastases (half-life, 22.9 h). The dose-escalation regimen was well tolerated; no dose-limiting toxicities or grade 3/4 hematologic adverse events were observed, even at the maximum administered activity of 7.4 GBq. Biochemical response was observed in most patients, with 8 of 9 (88.9%) demonstrating a decline in PSA levels from baseline. A 50% decline from baseline in PSA was achieved in 2 of 9 patients (22.2%). The magnitude of PSA reduction varied across administered activity levels. Conclusion: This phase 1 dose-escalation study showed rapid in vivo clearance of [177Lu]Lu-P17-087 and low early normal-organ toxicity in this small cohort. Administration of activities up to 7.4 GBq per cycle was feasible and was associated with preliminary antitumor activity. Larger studies with longer follow-up are required to define efficacy, safety, and the optimal dosing strategy.
引用
- Zhao R, Li M, Lv J, et al. Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [177Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy. J Nucl Med. 2026. PMID: 42785946. doi:10.2967/jnumed.126.272406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。